GO
Loading...

GlaxoSmithKline PLC

More

  • Sept 2- The U.S. Department of Health and Human Services said on Tuesday a federal contract worth up to $42.3 million would help accelerate testing of an experimental Ebola virus treatment that is being developed by privately held Mapp Biopharmaceutical Inc..

  • PRESS DIGEST-Sunday British Business - AUG 31 Sunday, 31 Aug 2014 | 9:28 AM ET

    LONDON, Aug 31- British newspapers reported the following business stories on Sunday. GlaxoSmithKline is facing a shareholder revolt over plans to shake up its board, with leading investors calling for the speedy departure of Chairman Christopher Gent.

  • The success is therefore a "monumental achievement," virologist Thomas Geisbert of the University of Texas Medical Branch wrote in a commentary on the paper, published online in Nature.

  • Aug 29- BioCryst Pharmaceuticals Inc said it expects to initiate a study within weeks to test its antiviral in primates for use against Ebola infections. This $2.4 million National Institute of Allergy and Infectious Diseases funding is in addition to the $22 million contract awarded to BioCryst by the agency last September.

  • He backed up a short bet; China jailed him for it Friday, 29 Aug 2014 | 12:00 AM ET
    Kun Huang, a Chinese-born Canadian citizen, who is back in Vancouver after spending two years in a Chinese jail, at his lawyer’s office in Vancouver, Canada, Aug. 22, 2014.

    His crime was contributing to research that led his employer to recommend short sales of Silvercorp Metals, a silver producer that is based in Canada but does its mining in China.

  • CHICAGO, Aug 28- Genetic studies of some of the earliest Ebola cases in Sierra Leone reveal more than 300 genetic changes in the virus as it leapt from person to person, changes that could blunt the effectiveness of diagnostic tests and experimental treatments now in development, researchers said on Thursday.

  • GENEVA/ LAGOS Aug 28- The Ebola epidemic in West Africa could infect more than 20,000 people, the U.N. health agency said on Thursday, warning that an international effort costing almost half a billion dollars is needed to overcome the outbreak.

  • US to begin safety testing Ebola vaccine next week Thursday, 28 Aug 2014 | 8:43 AM ET

    The National Institutes of Health announced Thursday that it is launching the safety trial on a vaccine developed by the agency's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline.

  • LONDON/ NEW YORK, Aug 28- An experimental Ebola vaccine from GlaxoSmithKline is being fast-tracked into human studies and the company plans to build a stockpile of up to 10,000 doses for emergency deployment, if results are good.

  • WINNIPEG, Manitoba, Aug 25- Four monkeys survived the Ebola virus after being injected with a vaccine that included Immunovaccine Inc's technology, the tiny Canadian company said on Monday, and the announcement sent its stock soaring.

  • *Drug has orphan drug status in US, EU and Japan. Aug 20- Amicus Therapeutics Inc moved a step closer to bringing its first drug to the market after trial results paved the way for its lead drug to become the first oral treatment for patients with a disorder that causes an abnormal build-up of fat.

  • Aug 20- Amicus Therapeutics Inc said its experimental drug was as effective as enzyme replacement therapies after 18 months in patients with Fabry disease, an inherited disorder that leads to the abnormal build-up of fat. The company's stock rose 38 percent in premarket trading on Wednesday after the results of the second late-stage trial were released.

  • P&G eyes Duracell, Braun in sweeping brand culling Monday, 18 Aug 2014 | 11:14 AM ET
    Procter & Gamble corporate headquarters in downtown Cincinnati.

    P&G is working with advisers to review up to 100 underperforming brands for potential divestiture.

  • NORWICH, England, Aug 17- Pampering leafcutter ants with fragrant rose petals and fresh oranges may seem an unlikely way to rescue modern medicine, but scientists at a lab in eastern England think it's well worth trying.

  • NEW YORK, Aug 13- Biotechnology company InterMune Inc is working with financial advisers to evaluate strategic options as it braces for potential takeover interest from larger drugmakers, people familiar with the matter said.

  • Aug 13- BioCryst Pharmaceuticals Inc said the U.S. government exercised options to test the company's antiviral drug in humans and non-primates as a treatment for hemorrhagic fever viruses such as Ebola.

  • *Liberia to treat infected doctors with trial drug ZMapp. LONDON/ GENEVA, Aug 12- People infected in the West African Ebola outbreak can be offered untested drugs, the World Health Organisation said on Tuesday, but the scarcity of supplies has raised questions about who gets priority access to treatment.

  • *Liberia to treat infected doctors with trial drug ZMapp. LONDON/ GENEVA, Aug 12- People infected in the West African Ebola outbreak can be offered untested drugs, the World Health Organisation said on Tuesday, but the scarcity of supplies raises questions about who gets priority access to treatment.

  • LONDON, Aug 12- World Health Organization experts fighting the world's worst outbreak of Ebola hope for improved supplies of experimental treatments and progress with a vaccine by the end of the year.

  • *KKR teams up with Rhone Capital for $3.1 bln takeover offer. HONG KONG, Aug 12- A KKR& Co- led takeover of Australia's Treasury Wine Estates Ltd would likely lead to a long and drastic overhaul, resulting in a much smaller but more profitable company, bankers familiar with the matter said.